Evidence map›Paper›PMID 37337227›Full record

ArticleItalian journal of pediatrics2023

Pediatricians' awareness of galenic drugs for children with special needs: a regional survey.

Francesca Burlo, Davide Zanon, Paola Minghetti, Valentina Taucar, Giulia Benericetti, Giada Bennati, Egidio Barbi, Lucia De Zen

Abstract readLetter
In one paragraph

Article in Italian journal of pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesca BurloDepartment of Medicine, Surgery, and Health Sciences, University of Trieste, Trieste, Italy. francesca.burlo@gmail.com.ORCID http://orcid.org/0000-0002-8915-5855
Davide ZanonPharmacy and Clinical Pharmacology Department, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Paola MinghettiDept. Scienze Farmaceutiche, Università degli Studi di Milano, Milano, Italy.
Valentina TaucarPediatric Palliative Care and Pain Service, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Giulia BenericettiPharmacy and Clinical Pharmacology Department, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Giada BennatiPharmacy and Clinical Pharmacology Department, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Egidio BarbiDepartment of Medicine, Surgery, and Health Sciences, University of Trieste, Trieste, Italy.
Lucia De ZenPediatric Palliative Care and Pain Service, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.

Funding

Ministero della Salute Ministero della Salute
6 · The paper itself

Abstract

The prevalence of children with medical complexity is increasing, therefore drug formulations must be updated in accordance with their needs. Furthermore, a different drug formulation may be also needed for patients who require a very low dosage which is not easily reachable with those of the industrial products or for those following a ketogenic diet. Galenic (or compounded) drugs have been recently pointed out as effective in treating children. Nonetheless, their knowledge among healthcare providers is limited. We investigated how much did pediatricians know about galenic compounds by a short questionnaire administered to family and hospital pediatricians and pediatric residents in Friuli Venezia Giulia, Italy. We collected answers from 65 family pediatricians (57,5%), 39 hospital pediatricians (36,1%), and 47 pediatric residents (41,2%). Overall, both family and hospital pediatricians substantially know what is a galenic compound and the indications to its use. Of note, most of pediatricians ignore which is the legislation that allows the galenic compounds' preparation and use, and which is the correct procedure to prescribe them. Moreover, half of the hospital pediatricians and one-third of the family ones erroneously stated that galenic formulations cost more or like the industrial products, and around the 15% of both categories affirmed that galenic compounds are less safe than the commercial product. In conclusion, the use of galenic drug may significantly improve children's and caregivers' quality of life. We believe that all pediatricians should be updated on this quite new and interesting topic.

Indexed as

Children with DisabilitiesCaregiversChildHumansPediatriciansQuality of LifeSurveys and QuestionnairesChildrenGalenic compoundsMagistral formulaMedical complexityPediatricians

Identifiers

PMID37337227
PMCPMC10280911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.